Freelance writer/analyst for The Motley Fool, BioWorld, Nature Biotechnology, and anyone else that will let me write at the intersection of drugs and business.

Search Tweets

Twitter Feed

@BiologyFool — 3,683 followers, 1,197 tweets

Sign of the oncology times: MS Word doesn't think monotherapy is a word and suggests it be changed to immunotherapy.
Yep. Would have put "extremely" rare example, but ran out of characters. 
$EXEL is rare example of when biotech loans work. Share price wouldn't be nearly this high if it had raised capital through 2ndary offering.
Show More